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Background: High expression of aldehyde dehydrogenase 1 (ALDH1) has been confirmed in many tumors. This
enzyme plays an important role in tumor proliferation, metastasis, and drug resistance. However, in the case of
papillary thyroid carcinoma (PTC), the relationship between ALDH1 expression and prognosis remains unknown.
Method: We used tissue microarrays to evaluate ALDH1A1 expression in 247 surgically resected PTC specimens
by immunochemistry, and correlated the findings with the clinicopathological parameters.
Result: ALDH1A1 levels were significantly higher than in normal thyroid tissues. Moreover, ALDH1A1 overexpression
was significantly associated with extrathyroid extension (P = 0.001), pT status (P < 0.001), pN status (P = 0.016)
and TNM stage (P < 0.001). The Kaplan-Meier survival analysis suggested that high ALDH1A1 expression reflects
a poorer lymph node recurrence-free survival (LN-RFS) and distant recurrence-free survival (DRFS) in PTC patients,
as compared with patients having low ALDH1A1 expression. Multivariate analysis confirmed the ALDH1A1
expression was an independent prognostic factor for LN-RFS and DRFS in PTC patients.
Conclusion: In conclusion, high ALDH1A1 expression correlates with poor survival in PTC patients.
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Thyroid carcinoma, a common endocrine malignancy,
is the fifth most common cancer in women. In recent
years, the incidence of thyroid cancer has shown a rising
trend [1]. Papillary thyroid carcinoma (PTC) accounts
for more than 80% of thyroid malignancies [2]. One of
the challenges surrounding thyroid cancers is that they
are difficult to detect in the early stages, because almost
no symptoms are present at that time. Generally, PTC
displays an indolent course and shows a ten-year sur-
vival rate of approximately 80%. However, this does not
mean that thyroid carcinoma cannot be progressive [3].
One of the challenges in this field is to identify PTC
patients who will exhibit a progressive course of the dis-
ease, without extrathyroid extension, distant metastases,
and tumor differentiation. Therefore, it is important to
find markers that could have prognostic value for thy-
roid carcinoma. The cancer stem cell hypothesis could
explain the occurrence of thyroid cancer and metastasis.* Correspondence: lihh8@163.com
Department of Thyroid Surgery, Sun Yat-Sen Memorial Hospital of Sun
Yat-Sen University, Guangzhou, Guangdong Province 510120, China
© 2014 Xing et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.According to this hypothesis, cancer stem cells are able
to self-renew, differentiate, and mediate the drug resist-
ance of the tumor [4]. Currently, a number of cancer stem
cell biomarkers have been identified, including CD133,
ALDH1, and IGF [5]. Based on the current study, ALDH1
is emerging as a promising biomarker to predict thyroid
cancer invasiveness.
In several human cancers, ALDH1 has been consi-
dered an important tumor marker. ALDH1 could be a
useful marker for cancer stem cells derived from tumors
that do not express high ALDH1 levels [6]. ALDH1 is an
enzyme involved in the intracellular synthesis of retinoic
acid, and ALDH1A1 is a major ALDH family member
that catalyzes the oxidation of retinal to retinoic acid [7].
This function plays an important role in promoting stem
cell differentiation [8]. Thyroid cancer cells with high
ALDH1 expression levels are tumorigenic and reproduce
the phenotypic characteristics of the original tumor [4].
ALDH1 is currently regarded as a marker of thyroid
cancer. However, the prognosis and clinical significance
of ALDH1A1 is not very clear, particularly in certain
histological types of thyroid cancer. In this study, tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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about the aggressive behavior of PTC, we proposed to
examine ALDH1A1 expression in PTC tissues and the
relationship between ALDH1A1 and known prognostic
factors.
Methods
Tissue samples and patients
Two hundred and forty-seven PTC patients treated sur-
gically between 2004 and 2010 at the Department of
Thyroid Surgery of the Sun Yat-Sen Memorial Hospital
of Sun Yat-Sen University were eligible for this study.
Before surgery, patients were not receiving any medica-
tion. All patients were newly diagnosed cases and under-
went total thyroidectomy or lobectomy. After surgery,
patients received radioactive iodine ablation according
to American Thyroid Association Guidelines [9]. De-
mographical and clinical data were collected from 247
patients with PTC for gender, age, pT status, pN status,
recurrence, extrathyroidal invasion and distant meta-
static dissemination. The patients were staged according
to the current TNM classification system. The tumor
specimens and 50 normal samples from adjacent tissues
were obtained as paraffin blocks from the department of
pathology of our hospital. All patients were followed up
for Tg level and ultrasound per six months. All proce-
dures were in compliance with the patient guidelines
and the ethical review process of our institution, and
were approved by the Institute Research Medical Ethics
Committee of China Medical University.
Immunohistochemistry
Before dewaxing, the tissue sections were placed in a
60°C baking oven for 20 minutes. Slides were deparaffi-
nized in xylene, rehydrated in a graded alcohol series,
and washed in PBS twice for five minutes each time.
Sections were heated in 10 mM sodium citrate buffer,
pH = 6.0, for 15 minutes in a 95°C water bath for antigen
retrieval. Until the buffer cooled down, we performed
five-minute PBS washes. Endogenous peroxidase activity
was blocked by incubating the sections in 3% H2O2 at
room temperature for ten minutes. Blocking serum was
added dropwise at room temperature for 20 minutes to
reduce the non-specific background. Anti-ALDH1A1
monoclonal antibodies (ab-134188; 1:100 dilution; Abcam,
Cambridge, MA, USA) were added and incubated over-
night at 4°C. The sections were washed in PBS three times
for two minutes, and subsequently incubated with bio-
tinylated secondary antibody (PK-4001; VECTASTAIN®
Elite ABC kits, Vector Labs, USA) for 30 minutes at room
temperature. The slides were subsequently incubated with
ABC (PK-4001; VECTASTAIN® Elite ABC kits, Vector
Labs, USA) for another 30 minutes, washed in PBS, and
stained with DAB (3, 3-diaminobenzidine). Finally, thesections were counterstained with Mayer’s hematoxylin,
dehydrated, and mounted.
Scoring of staining
ALDH1A1 mainly distributed in the cytoplasm of thyro-
cytes. Two investigators who were blinded to the patients’
clinicopathological characteristics scored the sections in-
dependently. Immunoreactivity was scored using a semi-
quantitative method as follows: (0) < 5% positive epithelial
cells; (1) from 5 to 20% positive; (2) from 20 to 50%
positive; (3) from 50 to 80% positive; and (4) more than
80% positive thyrocytes. The two scores were multiplied
in each case, and the expression was graded as nega-
tive (score = 0), low expression (score = 1 to 4), or high
(score = 5 to 12).
Statistical analysis
Data were analyzed by the SPSS software (standard version
16.0, SPSS, Chicago, IL, USA). The ability of ALDH1A1 to
predict the correlation between ALDH1A1 expression and
clinicopathological features was evaluated using Pearson’s
χ2 test. Lymph node recurrence-free survival (LN-RFS) and
distant recurrence-free survival (DRFS) were assessed using
the Kaplan-Meier method and compared by the log-rank
test. Multivariate survival analysis was performed for all
the parameters that were significant in the univariate ana-




All clinical and immunohistochemical data are shown in
Table 1. Eighty-nine patients were male with a mean age
of 43.9 ± 14.5 years (range, 23 to 72 years) and 158 pa-
tients were female with a mean age of 46.3 ± 14.9 years
(range, 21 to 83 years). Extrathyroid invasion of the
tumor was seen in 73 patients (29.5%) and lymph node
metastasis was positive in 76 patients (30.7%). According
to the TNM staging system, 78 patients (31.5%) were
classified as stage I, 55 (22.3%) as stage II, 69 (27.9%) as
stage III, and 45 (18.2%) as stage IV. Median follow-up
time was 47 months (range, 15 to 96 months), and
during this time, 18.6% of the patients (46 of 247) expe-
rienced lymph node recurrences and 9.3% (23 of 247)
developed distant organ recurrences.
ALDH1A1 expression
Immunostaining results were summarized in Table 1.
ALDH1A1 expression was significantly higher in ma-
lignant tumors than in non-malignant ones. ALDH1A1
expression was present in 78.9% (195/247) of the tumor
samples, but only in 32% of the samples from normal
and adjacent non-tumor tissues (Figure 1).
Figure 1 ALDH1A1 expression by immunohistochemical staining. (A)
case demonstrated high expression of ALDH1A1 (×200). (C) High expressio
(×200). (D) High expression of ALDH1A1 was detected in a PTC case with l
Table 1 Correlation between aldehyde dehydrogenase 1
A1 (ALDH1A1) expression and clinicopathological factors
Parameter Case ALDH1A1 P
Low High
Gender
Female 158 73 85 0.794
Male 89 43 46
Age
≤ 45 139 72 67 0.084
> 45 108 44 64
EI
Yes 73 28 45 0.001
No 174 108 66
PT status
1 85 61 24 < 0.001
2 64 23 41
3 82 28 54
4 16 4 12
ON status
0 76 27 49 0.016
1 171 89 82
TNM
I 78 50 28 < 0.001
II 55 29 26
III 69 24 45
IV 45 13 32
ALDH1A1 (low, the low expression of ALDH1A1; high, the high expression of
ALDH1A1); EI, extrathyroid invasion.
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As shown in Table 1, a high expression of ALDH1A1
was significantly correlated with extrathyroidal extension
(P = 0.023), pT status (P < 0.001), pN status (P = 0.016)
and TNM stage (P < 0.001). ALDH1A1 expression was
not correlated with age or gender. These data indicated
that ALDH1A1 expression in tumors can help identify
the degree of malignancy of thyroid cancer. The correl-
ation between ALDH1A1 expression levels and thyroid
cancer prognosis was analyzed with the Kaplan-Meier
method. We observed that ALDH1A1 expression in
PTC patients was significantly correlated with LN-RFS
(P = 0.007) and DR-FS (P = 0.008) (Table 2 and Figure 2).
When the aforementioned parameters were analyzed
in multivariate analysis, the results demonstrated that
ALDH1A1 expression was an independent indicator of
LN-RFS and DRFS (Table 3).
Discussion
As it is widely known, many tumors are not sensitive to
chemotherapy, and this is particularly true for thyroid
cancer. Many studies demonstrated that ALDH1 overex-
pression in cancer cell lines leads to resistance to che-
motherapy [10,11], which suggests that ALDH1 plays a
role in resistance, and indicates that it could provide im-
portant insights into understanding the molecular mech-
anisms of drug resistance in malignancies. In addition,
ALDHhigh cancer stem cells retain their tumor-initiating
capacity, and when ALDHhigh thyroid cancer spheres are
topically injected into the mouse thyroid gland, this can
lead to the formation of tumors and metastasis [4]. It
was revealed that the cancer stem cells that are enriched
in ALDH1 can easily lead to cancer recurrences.
According to these findings, the examination of
ALDH1A1 expression by immunohistochemistry emergesNormal thyroid tissue showed low expression of ALDH1A1. (B) PTC
n of ALDH1A1 was detected in a PTC case with extrathyroid invasion
ymph node metastasis (×200).
Table 3 Multivariate Cox regression analysis for survival
in papillary thyroid carcinoma (PTC)
LN-RFS DRFS
Variable RR 95% CI P RR 95% CI P
ALDH1A1 2.266 1.207 to 4.254 0.011 3.293 1.216 to 8.917 0.019
T status 1.518 1.292 to 1.932 0.038 2.204 1.134 to 5.276 0.021
N status 2.109 1.381 to 4.170 0.023 2.836 1.285 to 6.305 0.018
ALDH1A1 (low, the low expression of ALDH1A1; high, the high expression of
ALDH1A1); CI, confidence interval; RR, relative risk.
Figure 2 lymph node recurrence-free survival (LN-RFS) and
distant recurrence-free survival (DRFS) curves for papillary
thyroid carcinoma (PTC) patients according to their ALDH1A1
expression status. A, LN-RFS curves: patients with low and high
expression levels of ALDH1A1. B, DRFS curves: patients with low and
high expression levels of ALDH1A1.
Table 2 Univariate analysis of lymph node recurrence-
free survival (LN-RFS) and distant recurrence-free survival
(DRFS) in patients with papillary thyroid carcinoma (PTC)
(months, mean ± SE)
Variable Case LN-RFS P DRFS P
Gender
Female 158 63.0 ± 2.0 0.073 72.1 ± 1.6 0.362
Male 89 69.3 ± 2.3 72.9 ± 1.8
Age
< 45 139 65.3 ± 1.7 0.172 73.4 ± 1.5 0.216
> 45 108 64.9 ± 2.4 71.1 ± 1.9
EI
No 174 66.7 ± 1.7 0.036 73.4 ± 1.2 0.028
Yes 73
PT status
1 85 60.4 ± 3.4 0.017 68.1 ± 2.9 0.032
2 64 69.4 ± 2.1 74.1 ± 2.8
3 82
4 16 66.2 ± 1.8 70.3 ± 2.3
65.9 ± 1.3 69.4 ± 1.8
60.3 ± 2.5 63.5 ± 2.7
PN status
0 171 66.9 ± 1.7 0.028 73.3 ± 1.2 0.046
1 76 60.2 ± 3.2 68.6 ± 2.9
TNM
1 to 2 133 68.4 ± 2.2 0.047 75.1 ± 1.6 0.012
3 to 4 114 60.6 ± 1.9 64.7 ± 1.6
ALDH1A1
Low 116 69.5 ± 2.1 0.007 75.3 ± 1.2 0.008
High 131 61.6 ± 2.2 69.8 ± 1.9
ALDH1A1 (low, the low expression of ALDH1A1; high, the high expression of
ALDH1A1) EI, extrathyroid invasion.
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identify the patients with a high likelihood of relapse,
and this could help design novel therapeutic approa-
ches for PTC patients. The expression of ALDH1A1
by cancer stem cells can have dire consequences, and
this is consistent with our findings. Thus, ALDH1A1
may be a new therapeutic target with relevance in
thyroid carcinoma.
In this study, we have demonstrated that ALDH1A1 is
highly expressed in PTC patients. LN-RFS and DRFS are
much shorter in patients with high ALDH1A1 expression,
as compared to patients with low ALDH1A1 expression.
ALDH1A1 expression was highly correlated with factors
that can lead to poor prognosis, such as extrathyroidal
extension and lymph node metastasis. Our multivariate
analysis confirmed that, in PTC patients, ALDH1A1overexpression represents the only independent risk factor
for LN-RFS and DRFS. Taken together, our results reveal
that ALDH1A1 expression levels may be a prognostic in-
dicator in PTC patients.
It is widely accepted that surgical resection could
be considered the main therapeutic strategy in patients
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same TNM stage and have undergone the same surgical
approach, the prognosis appears to be different in every
individual. It is possible that there are some factors,
unknown yet, which are involved in shaping progno-
sis. In our study, high ALDH1A1 protein expression
has emerged as an independent prognostic factor for
poor LN-RFS and DRFS, as the multivariate survival ana-
lysis has demonstrated. Therefore, detecting ALDH1A1
expression might contribute to predicting the prognosis in
PTC patients. This factor seems to explain why different
prognostic outcomes appear to exist in patients who pre-
sent the same TNM stages.
ALDH1A1 expression presents clinical significance not
only in PTC, but also for other tumors. For example,
ALDH1A1 showed high expression in clear cell renal
cell carcinoma compared with normal tissues [7]. The
ALDH1A1 phenotype is an independent predictor of early
tumor relapse that is characteristic of invasive ductal car-
cinoma [12,13]. Moreover, increased ALDH1A1 expression
was associated with enhanced invasiveness in malignancies
such as acute myeloid leukemia [14], nasopharyngeal car-
cinoma [15], bladder cancer [16], and pancreatic cancer
[17]. However, in non-small cell lung carcinomas, loss of
ALDH1A1 expression was suggested to promote carcino-
genesis, particularly in smoking-related adenocarcinomas
[18]. These findings may imply that ALDH1A1 overexpres-
sion could be involved in accelerating the process of
tumorigenesis. In our study, ALDH1A1 has emerged as
the main factor associated with poor prognosis.
Our study has certain limitations. Firstly, we did not
perform a multi-center study so the number of partici-
pants may be insufficient. Secondly, some patients re-
ceived 131I treatment after surgery, which could decrease
the rate of recurrence, and may have influenced the re-
sults. Thirdly, this is a retrospective study.Conclusion
In summary, we demonstrated that ALDH1A1 is overex-
pressed in PTC. The expression level was correlated with
extrathyroidal extension of the tumor and lymph node
metastasis. ALDH1A1 may, therefore, be used as an indi-
cator of prognosis in patients with papillary thyroid can-
cer. However, the mechanisms that underlie this link are
not very clear, and further research needs to be performed
on this topic.Abbreviations
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